JP2023536618A5 - - Google Patents

Info

Publication number
JP2023536618A5
JP2023536618A5 JP2023507388A JP2023507388A JP2023536618A5 JP 2023536618 A5 JP2023536618 A5 JP 2023536618A5 JP 2023507388 A JP2023507388 A JP 2023507388A JP 2023507388 A JP2023507388 A JP 2023507388A JP 2023536618 A5 JP2023536618 A5 JP 2023536618A5
Authority
JP
Japan
Application number
JP2023507388A
Other languages
Japanese (ja)
Other versions
JP2023536618A (ja
JPWO2022031756A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044412 external-priority patent/WO2022031756A1/en
Publication of JP2023536618A publication Critical patent/JP2023536618A/ja
Publication of JP2023536618A5 publication Critical patent/JP2023536618A5/ja
Publication of JPWO2022031756A5 publication Critical patent/JPWO2022031756A5/ja
Pending legal-status Critical Current

Links

JP2023507388A 2020-08-05 2021-08-03 Csrp3(システイン及びグリシンリッチタンパク質3)遺伝子治療 Pending JP2023536618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061727P 2020-08-05 2020-08-05
US63/061,727 2020-08-05
PCT/US2021/044412 WO2022031756A1 (en) 2020-08-05 2021-08-03 Csrp3 (cysteine and glycine rich protein 3) gene therapy

Publications (3)

Publication Number Publication Date
JP2023536618A JP2023536618A (ja) 2023-08-28
JP2023536618A5 true JP2023536618A5 (https=) 2024-08-08
JPWO2022031756A5 JPWO2022031756A5 (https=) 2024-08-08

Family

ID=80118758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507388A Pending JP2023536618A (ja) 2020-08-05 2021-08-03 Csrp3(システイン及びグリシンリッチタンパク質3)遺伝子治療

Country Status (11)

Country Link
US (1) US20230257431A1 (https=)
EP (1) EP4192962A4 (https=)
JP (1) JP2023536618A (https=)
KR (1) KR20230042468A (https=)
CN (1) CN116234916A (https=)
AU (1) AU2021321410A1 (https=)
BR (1) BR112023001336A2 (https=)
CA (1) CA3184983A1 (https=)
IL (1) IL300187A (https=)
MX (1) MX2023000994A (https=)
WO (1) WO2022031756A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021572A1 (en) 2016-04-20 2017-10-26 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
EP3697452A4 (en) 2017-10-16 2021-11-24 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS
BR112020020841A2 (pt) 2018-04-11 2021-01-19 Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus Composições e métodos para transplante de célulastronco
CA3096293A1 (en) 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
MY209860A (en) 2020-02-13 2025-08-07 Tenaya Therapeutics Inc Gene therapy vectors for treating heart disease
JP2023538519A (ja) 2020-08-07 2023-09-08 スペースクラフト セブン リミテッド ライアビリティ カンパニー Aavベクターを使用したプラコフィリン-2(pkp2)遺伝子治療
EP4479543A1 (en) * 2022-02-18 2024-12-25 Ginkgo Bioworks, Inc. Gene therapy for arrhythmogenic cardiomyopathy
CA3255650A1 (en) * 2022-03-18 2023-09-21 Aavantibio, Inc. METHODS AND COMPOSITIONS FOR TREATING RBM20-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10004857A1 (de) * 2000-02-03 2001-08-16 Schering Ag MLP-Gen, Nukleinsäuren, Polypeptide und deren Verwendung
WO2009012176A2 (en) 2007-07-14 2009-01-22 The University Of Iowa Research Foundation Methods and compositions for treating brain diseases
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
IL248102B (en) 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
MX2019011046A (es) * 2017-03-17 2019-10-17 Res Inst Nationwide Childrens Hospital Administracion de vectores del virus adenoasociado de microdistrofina especifica del musculo para tratar la distrofia muscular.
SG11202002276VA (en) * 2017-09-20 2020-04-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
AU2019258830B2 (en) * 2018-04-27 2025-12-18 Universität Heidelberg Modified AAV capsid polypeptides for treatment of muscular diseases
US20210260215A1 (en) * 2018-06-08 2021-08-26 University Of Florida Research Foundation, Incorporated Aav cardiac gene therapy for cardiomyopathy
CN114450411A (zh) * 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023536618A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)